These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 2079381)

  • 1. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
    Altamura AC; Mauri MC; Girardi T; Panetta B
    Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluphenazine decanoate in acute and maintenance therapy of schizophrenia.
    Altamura AC; Mauri MC; Guercetti G; Cazzullo CL
    Prog Neuropsychopharmacol Biol Psychiatry; 1987; 11(5):613-23. PubMed ID: 3122268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W; Möller HJ; Walter K; Wittmann B; Krueger R; Trenk D
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect.
    Chouinard G; Annable L; Ross-Chouinard A
    Am J Psychiatry; 1982 Mar; 139(3):312-8. PubMed ID: 6120655
    [No Abstract]   [Full Text] [Related]  

  • 10. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive and negative symptoms, depression and social disability in chronic schizophrenia: a comparative trial of bromperidol and fluphenazine decanoates.
    McLaren S; Cookson JC; Silverstone T
    Int Clin Psychopharmacol; 1992 Nov; 7(2):67-72. PubMed ID: 1487623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparison between the effectiveness of fluphenazine decanoate and oxyprothepin decanoate in schizophrenia (double-blind crossover study)].
    Balon R; Kabesh Ia; Papezhova G
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1982; 82(1):116-8. PubMed ID: 6121437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A long term comparative trial of penfluridol and fluphenazine decanoate in schizophrenic outpatients.
    Iqbal MJ; Young MA; Charles J; Elgart B; Von Greiff H; Simpson GM
    J Clin Psychiatry; 1978 Apr; 39(4):375-9. PubMed ID: 580285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluphenazine decanoate, oral fluphenazine, and placebo in the treatment of remitted schizophrenics. II. Rating scale data [proceedings].
    Rifkin A; Quitkin F; Kane J; Klein DF
    Psychopharmacol Bull; 1977 Apr; 13(2):49-50. PubMed ID: 323910
    [No Abstract]   [Full Text] [Related]  

  • 17. Pimozide versus fluphenazine in ambulatory schizophrenics: A 12-month comparison study.
    Donlon PT; Swaback DO; Osborne ML
    Dis Nerv Syst; 1977 Feb; 38(2):119-23. PubMed ID: 319967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The initiation of long-term pharmacotherapy in schizophrenia: dosage and side effect comparisons between oral and depot fluphenazine.
    Schooler NR; Levine J
    Pharmakopsychiatr Neuropsychopharmakol; 1976 Jul; 9(4):159-69. PubMed ID: 790413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of fluphenazine in plasma after decanoate withdrawal.
    Gitlin MJ; Midha KK; Fogelson D; Nuechterlein K
    J Clin Psychopharmacol; 1988 Feb; 8(1):53-6. PubMed ID: 3351000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.